Renal stones and calcifications in patients with primary hyperparathyroidism: Associations with biochemical variables

European Journal of Endocrinology

Volumn 166, Issue 6, 2012, Pages 1093-1100

  Starup Linde, Jakob ^a   Waldhauer, Elin ^a   Rolighed, Lars ^a   Mosekilde, Leif ^a   Vestergaard, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CREATININE;

ARTICLE; CALCIUM URINE LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; KIDNEY CALCIFICATION; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; PARATHYROIDECTOMY; PREDICTOR VARIABLE; PREVALENCE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RISK FACTOR; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

ADULT; AGED; BIOLOGICAL MARKERS; CALCIUM; CREATININE; DENMARK; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; KIDNEY CALCULI; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEPHROCALCINOSIS; PREVALENCE; TOMOGRAPHY, SPIRAL COMPUTED;

EID: 84862743709     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0032     Document Type: Article

References (38)

1. Knoll T, Schubert AB, Fahlenkamp D, Leusmann DB, Wendt-Nordahl G & Schubert G. Urolithiasis through the ages: data on more than 200,000 urinary stone analyses. Journal of Urology 2011 185 1304-1311. (doi:10.1016/j.juro.2010. 11.073)
2. Fraser WD. Hyperparathyroidism. Lancet 2009 374 145-158. (doi:10.1016/S0140-6736(09)60507-9)
3. Vestergaard P & Mosekilde L. Incidens af primær hyperparatyroidisme, hyppighed af operation og mortalitet belyst ved data fra Landspatientregistret. Ugeskrift for Laeger 2004 166 41-45. (Pubitemid 38159985)
4. Turney BW, Reynard JM, Noble JG & Keoghane SR. Trends in urological stone disease. BJU International 2012 109 1082-1087. (doi:10.1111/j.1464-410X. 2011.10495.x)
5. Siilin H, Lundgren E, Mallmin H, Mellstrom D, Ohlsson C, Karlsson M, Orwoll E & Ljunggren O. Prevalence of primary hyperparathyroidism and impact on bone mineral density in elderly men: MrOs Sweden. World Journal of Surgery 2011 35 1266-1272. (doi:10.1007/s00268-011-1062-2)
6. Yu N, Donnan PT, Murphy MJ & Leese GP. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clinical Endocrinology 2009 71 485-493. (doi:10.1111/j.1365-2265.2008. 03520.x)
7. Hackett DA & Kauffman GL Jr. Historical perspective of parathyroid disease. Otolaryngologic Clinics of North America 2004 37 689-700, vii. (doi:10.1016/j.otc.2004.02.003)
8. Andersen P & Mosekilde L. Tubular reabsorption of phosphate and calcium in primary hyperparathyroidism. Acta Medica Scandinavica 1972 191 565-572.
9. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001 142 5050-5055. (doi:10.1210/en.142.12.5050)
10. Parks JH, Coe FL, Evan AP & Worcester EM. Clinical and laboratory characteristics of calcium stone-formers with and without primary hyperparathyroidism. BJU International 2009 103 670-678. (doi:10.1111/j.1464- 410X.2008.08064.x)
11. Mosekilde L. Primary hyperparathyroidism and the skeleton. Clinical Endocrinology 2008 69 1-19. (doi:10.1111/j.1365-2265. 2007.03162.x)
12. Parfitt AM. The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone diseases. II. PTH and bone cells: bone turnover and plasma calcium regulation. Metabolism: Clinical and Experimental 1976 25 909-955. (doi:10.1016/0026-0495(76)90124-4)
13. Moosgaard B, Christensen SE, Vestergaard P, Heickendorff L, Christiansen P & Mosekilde L. Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clinical Endocrinology 2008 68 707-715. (doi:10.1111/j.1365-2265.2007. 03109.x)
14. Perez AV, Picotto G, Carpentieri AR, Rivoira MA, Peralta Lopez ME & Tolosa de Talamoni NG. Minireview on regulation of intestinal calcium absorption. Emphasis on molecular mechanisms of transcellular pathway. Digestion 2008 77 22-34. (doi:10.1159/000116623)
15. Dusso AS, Brown AJ & Slatopolsky E. Vitamin D. American Journal of Physiology. Renal Physiology 2005 289 F8-F28. (doi:10.1152/ajprenal.00336.2004)
16. Park S & Pearle MS. Pathophysiology and management of calcium stones. Urologic Clinics of North America 2007 34 323-334. (doi:10.1016/j.ucl.2007.04. 009)
17. Odvina CV, Sakhaee K, Heller HJ, Peterson RD, Poindexter JR, Padalino PK & Pak CY. Biochemical characterization of primary hyperparathyroidism with and without kidney stones. Urological Research 2007 35 123-128. (doi:10.1007/s00240-007-0096-2)
18. Suh JM, Cronan JJ & Monchik JM. Primary hyperparathyroidism: is there an increased prevalence of renal stone disease? AJR. American Journal of Roentgenology 2008 191 908-911. (doi:10.2214/AJR.07.3160)
19. Pak CY, Nicar MJ, Peterson R, Zerwekh JE & Snyder W. A lack of unique pathophysiologic background for nephrolithiasis of primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 1981 53 536-542. (doi:10.1210/jcem-53-3-536)
20. Soreide JA, van Heerden JA, Grant CS, Lo CY & Ilstrup DM. Characteristics of patients surgically treated for primary hyperparathyroidism with and without renal stones. Surgery 1996 120 1033-1037 (discussion 1037-8). (doi:10.1016/S0039-6060(96)80051-1)
21. Frokjaer VG & Mollerup CL. Primary hyperparathyroidism: renal calcium excretion in patients with and without renal stone disease before and after parathyroidectomy. World Journal of Surgery 2002 26 532-535. (doi:10.1007/s00268-001-0262-6)
22. Mollerup CL & Lindewald H. Renal stones and primary hyperparathyroidism: natural history of renal stone disease after successful parathyroidectomy. World Journal of Surgery 1999 23 173-175 (discussion 176). (doi:10.1007/PL00013175)
23. Mollerup CL, Vestergaard P, Frokjaer VG, Mosekilde L, Christiansen P & Blichert-Toft M. Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. BMJ 2002 325 807. (doi:10.1136/bmj.325.7368.807)
24. Wu B, Haigh PI, Hwang R, Ituarte PH, Liu IL, Hahn TJ & Yeh MW. Underutilization of parathyroidectomy in elderly patients with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2010 95 4324-4330. (doi:10.1210/jc.2009-2819)
25. Rejnmark L, Vestergaard P & Mosekilde L. Nephrolithiasis and renal calcifications in primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2011 96 2377-2385. (doi:10.1210/jc.2011-0569)
26. Berger AD, Wu W, Eisner BH, Cooperberg MR, Duh QY & Stoller ML. Patients with primary hyperparathyroidism - why do some form stones? Journal of Urology 2009 181 2141-2145. (doi:10.1016/j.juro.2009.01.028)
27. D'Angelo A, Lodetti MG, Giannini S, Castrignano R, al Awady M, Malvasi L, Fabris A & Maschio G. Hyperparathyroidism: cause or consequence of recurrent calcium nephrolithiasis? Mineral and Electrolyte Metabolism 1992 18 359-364. (Pubitemid 23016167)
28. Sakhaee K, Poindexter JR, Griffith CS & Pak CY. Stone forming risk of calcium citrate supplementation in healthy postmenopausal women. Journal of Urology 2004 172 958-961. (doi:10.1097/01.ju.0000136400.14728.cd)
29. Bandeira F, Caldas G, Freese E, Griz L, Faria M & Bandeira C. Relationship between serum vitamin D status and clinical manifestations of primary hyperparathyroidism. Endocrine Practice 2002 8 266-270.
30. Christensen SE, Nissen PH, Vestergaard P, Heickendorff L, Brixen K & Mosekilde L. Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clinical Endocrinology 2008 69 713-720. (doi:10.1111/j.1365-2265.2008.03259.x)
31. Souberbielle JC, Lawson-Body E, Hammadi B, Sarfati E, Kahan A & Cormier C. The use in clinical practice of parathyroid hormone normative values established in vitamin D-sufficient subjects. Journal of Clinical Endocrinology and Metabolism 2003 88 3501-3504. (doi:10.1210/jc.2003-030097)
32. Hojskov CS, Heickendorff L & Moller HJ. High-throughput liquid-liquid extraction and LCMSMS assay for determination of circulating 25(OH) vitamin D3 and D2 in the routine clinical laboratory. Clinica Chimica Acta 2010 411 114-116. (doi:10.1016/j.cca.2009.10.010)
33. Heymsfield SB, Arteaga C, McManus C, Smith J & Moffitt S. Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. American Journal of Clinical Nutrition 1983 37 478-494. (Pubitemid 13086433)
34. Mollerup CL, Bollerslev J & Blichert-Toft M. Primary hyperparathyroidism: incidence and clinical and biochemical characteristics. A demographic study. European Journal of Surgery 1994 160 485-489. (Pubitemid 24306981)
35. Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen PM, Blichert-Toft M & Mosekilde L. Cohort study of fracture risk before and after surgery of primary hyperparathyroidism. Ugeskrift for Laeger 2001 163 4875-4878. (Pubitemid 33607038)
36. Moosgaard B, Vestergaard P, Heickendorff L & Mosekilde L. Plasma 1,25-dihydroxyvitamin D levels in primary hyperparathyroidism depend on sex, body mass index, plasma phosphate and renal function. Clinical Endocrinology 2007 66 35-42. (Pubitemid 44952492)
37. Stamatelou KK, Francis ME, Jones CA, Nyberg LM & Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney International 2003 63 1817-1823. (doi:10.1046/j.1523-1755.2003.00917.x)
38. Christensen SE, Nissen PH & Schwarz P. Investigation and diagnosis of familial hypocalciuric hypercalcemia in Denmark. Ugeskrift for Laeger 2005 167 905-910. (Pubitemid 40341153)